



1631
A34535-A-PCT-USA-A (070050.1866)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Fisher *et al.*
Serial No. : 09/991,452 Examiner : Marschel, A.
Filed : November 21, 2001 Group Art Unit: 1631
For : USE OF A MELANOMA DIFFERENTIATION ASSOCIATED
GENE (mda-7) FOR REVERSING A CANCEROUS
PHENOTYPE

RECEIVED
AUG 08 2003
TECH CENTER 1001/25-30

**RESPONSE TO RESTRICTION REQUIREMENT
AND AMENDMENT**

I hereby certify that this paper is being deposited with the United States
Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, Alexandria, VA 22313-1450

August 4, 2003

Date of Deposit

Lisa B. Kole

Attorney Name

Lisa B. Kole
Signature

35,225

PTO Registration No.

July 31, 2003

Date of Signature

Commissioner for Patents
Box 1450
Alexandria, Virginia 22313-1450

SIR:

In response to the Restriction Requirement dated March 5, 2003,

Applicants hereby elect to pursue the claim of Group II, drawn to a method of treating a melanoma in a subject via administration of a mda-7 protein, in the instant application. This election is made without prejudice to the prosecution of non-elected claims 1 and 2 in other patent applications.

Applicants submit herewith a Petition to Extend Time for their response to the Restriction Requirement for a period of four months, together with the required fee.

In addition, it is requested that the following amendments and remarks be made of record.